Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 3.86B P/E - EPS this Y 58.80% Ern Qtrly Grth -
Income -147.07M Forward P/E 96.86 EPS next Y 214.30% 50D Avg Chg 7.00%
Sales 423.49M PEG 0.31 EPS past 5Y - 200D Avg Chg 13.00%
Dividend N/A Price/Book 37.46 EPS next 5Y -147.10% 52W High Chg -2.00%
Recommedations 1.80 Quick Ratio 2.22 Shares Outstanding 296.20M 52W Low Chg 49.00%
Insider Own 0.72% ROA -5.08% Shares Float 238.52M Beta 0.79
Inst Own 109.62% ROE -126.10% Shares Shorted/Prior 28.91M/31.32M Price 13.56
Gross Margin 89.62% Profit Margin -34.73% Avg. Volume 2,768,937 Target Price 17.33
Oper. Margin -19.63% Earnings Date Aug 6 Volume 1,757,132 Change 1.12%
About Amicus Therapeutics, Inc.

Amicus Therapeutics, Inc., a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset. It has collaboration and license agreements with the University of Pennsylvania to research and develop parvovirus gene therapy products; and GlaxoSmithKline. Amicus Therapeutics, Inc. was incorporated in 2002 and is headquartered in Princeton, New Jersey.

Amicus Therapeutics, Inc. News
05/24/24 Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
05/10/24 Amicus Therapeutics, Inc. (NASDAQ:FOLD) Q1 2024 Earnings Call Transcript
05/10/24 Amicus Therapeutics Inc (FOLD) Q1 2024 Earnings: Surpasses Revenue Estimates and Projects ...
05/10/24 Amicus (FOLD) Q1 Earnings Top, Sales Lag, '24 Outlook Updated
05/09/24 Amicus Therapeutics (FOLD) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
05/09/24 Amicus Therapeutics (FOLD) Reports Q1 Loss, Lags Revenue Estimates
05/09/24 Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates
05/08/24 Amicus Therapeutics to Present at the Bank of America 2024 Health Care Conference
05/03/24 ANI Pharmaceuticals (ANIP) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
05/01/24 Will Amicus Therapeutics (FOLD) Report Negative Q1 Earnings? What You Should Know
05/01/24 Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024
04/19/24 When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Become Profitable?
03/29/24 Why Is Amicus Therapeutics (FOLD) Down 8.1% Since Last Earnings Report?
03/20/24 Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report
03/13/24 13 Best Biotech Stocks To Buy Under $20
03/06/24 Director Margaret Mcglynn Sells 15,000 Shares of Amicus Therapeutics Inc (FOLD)
03/05/24 Amicus Therapeutics Stock Sees RS Rating Improve To 74
03/02/24 Amicus Therapeutics, Inc. (NASDAQ:FOLD) Just Reported Annual Earnings: Have Analysts Changed Their Mind On The Stock?
03/01/24 Amicus Therapeutics Full Year 2023 Earnings: EPS Misses Expectations
03/01/24 Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024
FOLD Chatroom

User Image Hottehueh Posted - 1 week ago

$FOLD Starter. Cheap down here

User Image victorcastro Posted - 2 weeks ago

$COUR $DBD $FOLD $MEOH $PZZA

User Image valueforme Posted - 2 weeks ago

$FOLD Added

User Image HorizonBull Posted - 2 weeks ago

$FOLD huge undervalue.

User Image txmdgod Posted - 2 weeks ago

$FOLD revenue and guidance look great but why are we spending so much per quarter. Costs need to come down. This is the simple answer to why share price has sucked the last few quarters. I can't believe I'm saying this but burning this amount per quarter could still leave dilution on the table at some point. C'mon management let's see a cost plan or sell the damn company.

User Image PDM5 Posted - 2 weeks ago

$FOLD OK, time for a buyer. Cut the fat and boost production

User Image valueforme Posted - 2 weeks ago

$FOLD Delivered a decent quarter, but the share price will likely stay depressed. They need to cut costs more and accelerate path to profitability. Share based comp is too high IMHO, which adds pressure to GAAP numbers. Overall, they look solid and predictable.

User Image Estimize Posted - 2 weeks ago

$FOLD misses the Estimize EPS Consensus by 11c and the Estimize Revenue Consensus by $2.71M. Reports FQ1 earnings of -16c EPS and $110.... http://www.estimize.com/fold/fq1-2024?utm_content=beat_or_miss&utm_medium=tweet&utm_source=stocktwits

User Image epsguid Posted - 2 weeks ago

$FOLD reported a loss of $0.02, consensus was ($0.06) via @eWhispers #epsbeat http://eps.sh/d/fold

User Image Stock_Titan Posted - 2 weeks ago

$FOLD Amicus Therapeutics Announces First Quarter 2024 Financial Results and Corporate Updates https://www.stocktitan.net/news/FOLD/amicus-therapeutics-announces-first-quarter-2024-financial-results-qwqb44q84f68.html

User Image Doozio Posted - 2 weeks ago

$fold them dingleberries or INOD to a 🐑 tell?

User Image Estimize Posted - 2 weeks ago

$FOLD reports before the open tomorrow, Estimize Consensus +0.02 EPS and +1.93M Revs compared to WS http://www.estimize.com/fold/fq1-2024?utm_content=prerelease&utm_medium=tweet&utm_source=stocktwits

User Image shakky Posted - 2 weeks ago

$FOLD load up before earnings.This will pop 30% after earnings.

User Image Stock_Titan Posted - 3 weeks ago

$FOLD Amicus Therapeutics to Announce First Quarter 2024 Financial Results on May 9, 2024 https://www.stocktitan.net/news/FOLD/amicus-therapeutics-to-announce-first-quarter-2024-financial-results-l57nth25arnh.html

User Image valueforme Posted - 4 weeks ago

$FOLD $MIRM $BCRX This is getting ridiculous

User Image StockDeni Posted - 1 month ago

$FOLD

User Image Aigner_Andreas Posted - 1 month ago

#DeathCross $FOLD at 10.33 R10 HiLo 8% T1Y 15 buy 2.1 DIV N/A #Amicus The #stocks #trading #finance #market

User Image skgg Posted - 1 month ago

$FOLD is anything happening here?

User Image TeeMan123 Posted - 2 months ago

$FOLD ok Bradley, lets get two more qtrs of strong revenue growth on the new pompe franchise, and get a deal done with Biogen... time to send the baby to large pharma and the new-Biogen with a focus in rare disease would be a perfect fit

User Image Enzan Posted - 2 months ago

$FOLD Meh... cut it loose for -2.5%

User Image Stock_Titan Posted - 2 months ago

$FOLD Amicus Therapeutics Issues 2024 Environmental, Social, and Governance (ESG) Report https://www.stocktitan.net/news/FOLD/amicus-therapeutics-issues-2024-environmental-social-and-governance-l8demvy857fv.html

User Image Enzan Posted - 2 months ago

$FOLD New long

User Image erevnon Posted - 2 months ago

JP Morgan maintains Amicus Therapeutics $FOLD at Overweight and lowers the price target from $21 to https://marketsblock.com/stock-upgrades-and-downgrades/

User Image insiderbuyingselling Posted - 2 months ago

$FOLD new insider selling: 31614 shares. http://insiderbuyingselling.com/?t=FOLD

User Image Kenzie1 Posted - 2 months ago

$FOLD Let’s hope Amicus starts to live up to their press. Shareholders have been waiting a long time. 13 Best Biotech Stocks To Buy Under $20 https://finance.yahoo.com/news/13-best-biotech-stocks-buy-110733423.html

User Image txmdgod Posted - 2 months ago

$FOLD have a feeling 2024 is the year. Fold will be sold for 26 bucks a share.

User Image TeeMan123 Posted - 2 months ago

$FOLD from what i can tell the weakness the past few days is around more news around WuXi and possible additional restrictions being sought by Congress... it is annoying the stock gets hit every time this is in the news, when FOLD already has a plan to move all of manufacturing to WuXi Ireland in 2025

User Image shakky Posted - 2 months ago

$FOLD WTF 😳 is going on?

User Image ToRni27 Posted - 2 months ago

$FOLD $SNY You will suffer! Elfabrio superior granted by PLX_BULLS!! 🚀🚀👊🫡

User Image Stock_Titan Posted - 2 months ago

$FOLD Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2024 https://www.stocktitan.net/news/FOLD/amicus-therapeutics-to-present-at-upcoming-investor-conferences-in-4azn58030dq3.html

Analyst Ratings
Guggenheim Buy May 14, 24
UBS Buy May 10, 24
Morgan Stanley Overweight May 10, 24
B of A Securities Buy May 10, 24
Needham Hold May 10, 24
JP Morgan Overweight Mar 18, 24
Cantor Fitzgerald Overweight Feb 29, 24
Morgan Stanley Overweight Dec 19, 23
Morgan Stanley Equal-Weight Nov 9, 23
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
Campbell Bradley L President and CEO President and CEO Feb 01 Sell 12.56 15,833 198,862 875,386 02/05/24
Campbell Bradley L President and CEO President and CEO Feb 01 Option 10.45 15,833 165,455 891,219 02/05/24
Crowley John F Executive Chairman Executive Chairman Feb 01 Sell 12.62 31,614 398,969 750,838 02/05/24
Crowley John F Executive Chairman Executive Chairman Jan 22 Sell 12.3621 55,327 683,958 782,452 01/24/24
Crowley John F Executive Chairman Executive Chairman Jan 09 Sell 13.65 31,614 431,531 869,393 01/11/24
Clark David Michael Chief People Officer Chief People Officer Jan 08 Sell 14 10,110 141,540 266,705 01/09/24
Prout Samantha Chief Accounting Off.. Chief Accounting Officer Jan 08 Sell 14 32,104 449,456 80,953 01/09/24
Campbell Bradley L President and CEO President and CEO Jan 02 Sell 14.23 15,833 225,304 947,805 01/04/24
Campbell Bradley L President and CEO President and CEO Jan 02 Option 10.45 15,833 165,455 956,138 01/04/24
Rosenberg Ellen Chief Legal Officer Chief Legal Officer Jan 02 Sell 14.21 30,000 426,300 342,285 01/04/24
Rosenberg Ellen Chief Legal Officer Chief Legal Officer Jan 02 Option 5.16 30,000 154,800 372,285 01/04/24
Castelli Jeff Chief Development Of.. Chief Development Officer Dec 28 Sell 14.5171 17,421 252,902 340,661 12/29/23
Prout Samantha Chief Accounting Off.. Chief Accounting Officer Dec 26 Sell 14.0003 7,659 107,228 121,912 12/28/23
Rosenberg Ellen Chief Legal Officer Chief Legal Officer Dec 26 Sell 14.03 35,000 491,050 342,285 12/28/23
Rosenberg Ellen Chief Legal Officer Chief Legal Officer Dec 26 Option 5.16 35,000 180,600 347,285 12/28/23
Castelli Jeff Chief Development Of.. Chief Development Officer Dec 18 Sell 13.18 19,154 252,450 358,082 12/20/23
Crowley John F Executive Chairman Executive Chairman Dec 15 Sell 12.66 6,043 76,504 877,748 12/19/23
Crowley John F Executive Chairman Executive Chairman Dec 01 Sell 11.0800 6,043 66,956 883,791 12/05/23
Crowley John F Executive Chairman Executive Chairman Nov 15 Sell 10.8385 6,043 65,497 889,834 11/17/23
Campbell Bradley L President and CEO President and CEO Nov 01 Sell 10.97 11,700 128,349 792,161 11/03/23
Campbell Bradley L President and CEO President and CEO Nov 01 Option 2.94 11,700 34,398 803,861 11/03/23
Crowley John F Executive Chairman Executive Chairman Nov 01 Sell 10.9741 6,044 66,327 895,877 11/03/23
Crowley John F Executive Chairman Executive Chairman Oct 16 Sell 10.4979 6,044 63,449 901,921 10/18/23
Crowley John F Executive Chairman Executive Chairman Oct 02 Sell 11.39 6,044 68,841 907,965 10/04/23
Campbell Bradley L President & CEO President & CEO Oct 02 Option 2.94 11,700 34,398 803,861 10/04/23
Campbell Bradley L President & CEO President & CEO Oct 02 Sell 11.62 11,700 135,954 792,161 10/04/23
Crowley John F Executive Chairman Executive Chairman Sep 15 Sell 13.0648 6,044 78,964 914,009 09/18/23
Crowley John F Executive Chairman Executive Chairman Sep 01 Sell 12.9794 6,044 78,447 920,053 09/06/23
Campbell Bradley L President & CEO President & CEO Sep 01 Sell 12.97 18,093 234,666 792,161 09/06/23
Campbell Bradley L President & CEO President & CEO Sep 01 Option 2.94 11,700 34,398 810,254 09/06/23
Crowley John F Executive Chairman Executive Chairman Aug 15 Sell 13.0268 6,044 78,734 926,097 08/16/23
Prout Samantha Chief Accounting Off.. Chief Accounting Officer Aug 09 Sell 14.01 36,909 517,095 137,003 08/11/23
Prout Samantha Chief Accounting Off.. Chief Accounting Officer Aug 09 Option 10.43 36,909 384,961 173,912 08/11/23
Crowley John F Executive Chairman Executive Chairman Jul 17 Sell 13.4453 6,044 81,263 938,185 07/19/23
Campbell Bradley L President & CEO President & CEO Jul 12 Sell 12.51 8,300 103,833 806,854 07/14/23
Crowley John F Executive Chairman Executive Chairman Jul 03 Sell 12.3107 6,044 74,406 944,229 07/06/23
Campbell Bradley L President & CEO President & CEO Jul 03 Option 2.94 11,700 34,398 826,854 07/06/23
Campbell Bradley L President & CEO President & CEO Jul 03 Sell 12.31 11,700 144,027 815,154 07/06/23
Crowley John F Executive Chairman Executive Chairman Jun 01 Sell 11.3596 6,044 68,657 956,317 06/05/23
Campbell Bradley L President & CEO President & CEO Jun 01 Sell 11.36 11,700 132,912 823,454 06/05/23
Campbell Bradley L President & CEO President & CEO Jun 01 Option 2.7 11,700 31,590 835,154 06/05/23
SBLENDORIO GLENN Director Director May 18 Option 3.32 15,000 49,800 86,719 05/19/23
Crowley John F Executive Chairman Executive Chairman May 15 Sell 11.1808 6,044 67,577 962,361 05/17/23
Crowley John F Executive Chairman Executive Chairman Apr 17 Sell 11.6648 6,044 70,502 974,449 04/19/23
Crowley John F Executive Chairman Executive Chairman Apr 03 Sell 11.2156 6,044 67,787 980,493 04/05/23
Campbell Bradley L President & CEO President & CEO Apr 03 Sell 11.21 11,700 131,157 823,454 04/05/23
Campbell Bradley L President & CEO President & CEO Apr 03 Option 2.45 11,700 28,665 835,154 04/05/23
RAAB MICHAEL Director Director Mar 17 Sell 11.33 4,408 49,943 60,012 03/21/23
RAAB MICHAEL Director Director Mar 17 Option 3.32 15,000 49,800 64,420 03/21/23
Crowley John F Executive Chairman Executive Chairman Mar 15 Sell 11.3414 6,044 68,547 986,537 03/17/23